US EditionAbbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress
- Abbisko Therapeutics revealed new findings from their phase 2 trial evaluating irpagratinib combined with atezolizumab in patients with advanced hepatocellular carcinoma, which will be shared at the 2025 ESMO GI Congress in Barcelona.
- The study targets FGF19+ HCC patients, around 30% of global cases, with no FGFR4 inhibitor approved to date, reflecting urgent need for new therapies.
- The oral presentation will focus on the regimen’s encouraging anti-tumor effects and well-tolerated safety profile observed in FGF19+ patients who are either newly diagnosed or have undergone prior treatment.
- In earlier clinical data, a regimen of 220mg irpagratinib taken twice daily combined with atezolizumab showed a 50% objective response rate in FGF19-positive HCC patients who had previously undergone immune checkpoint inhibitor treatment.
- These findings suggest irpagratinib-based combinations may offer a novel, potentially breakthrough treatment for advanced HCC with FGF19 overexpression.
36 Articles
36 Articles
Montana Standard
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress
SHANGHAI, May 12, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at…
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr - Finnoexpert
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr Source link The post Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr appeared first on Finnoexp…
Coverage Details
Bias Distribution
- 86% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
